SynthesisFrontiers in psychiatry2026
Preliminary efficacy of pharmacological treatments on sluggish cognitive tempo (cognitive disengagement syndrome): a systematic review and meta-analysis.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sluggish cognitive tempo (SCT), also referred to as cognitive disengagement syndrome (CDS), is characterized by symptoms such as mental fogginess, slowed behavior, daydreaming, and reduced alertness. It is increasingly recognized as a construct distinct from attention-deficit/hyperactivity disorder (ADHD). This systematic review and meta-analysis aimed to evaluate the effectiveness of pharmacological interventions on SCT/CDS-related outcomes. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science. Studies assessing pharmacological treatments with reported SCT/CDS outcomes were included. The primary quantitative synthesis focused on randomized controlled trials and crossover designs, while open-label studies were analyzed qualitatively. Standardized mean differences (Hedges' g) were calculated using a small-k-robust random-effects model (Paule-Mandel τ² estimator with Hartung-Knapp adjustment). A 95% prediction interval was additionally reported. Results: A total of seven studies were included in the qualitative synthesis, of which three (43%) provided sufficient data for meta-analysis. The total sample sizes of individual studies were generally small, contributing to limited statistical power. Using a small-k-robust random-effects model (Paule-Mandel τ² with Hartung-Knapp adjustment), the pooled effect was g=0.39 (95% CI: 0.01-0.78). The 95% prediction interval was -0.06 to 0.85. Between-study heterogeneity ranged from moderate to high (I² > 50%), reflecting variability in study design, pharmacological agents, outcome measures, and population characteristics. Discussion: Preliminary evidence suggests that pharmacological treatments, particularly atomoxetine and methylphenidate, may be associated with moderate improvements in SCT/CDS symptoms. However, given the limited number of controlled trials and the heterogeneity in populations (e.g., ADHD with comorbid dyslexia), these findings should be considered exploratory. Further large-scale RCTs are necessary to confirm these results and establish personalized treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.